Wellgistics Health, Inc. and Tollo Health, LLC Collaborate to Market Novel Medical Food Products for GLP-1 Treatment Side Effects and Long COVID
Tampa, Florida, February 26, 2025 – Wellgistics Health, Inc. (WGRX), a holding company focusing on healthcare technology and pharmaceutical services, has recently announced a new collaboration with Tollo Health, LLC. This partnership will see Wellgistics marketing Tollo’s innovative, proprietary suite of medical food products designed to help manage side effects of GLP-1 drugs and support patients with Long COVID. Tollo’s offerings include solutions for muscle loss, gut discomfort, and other symptoms related to GLP-1 treatments and persistent viral infections.
Addressing the Challenges of GLP-1 Drug Use
GLP-1 (Glucagon-Like Peptide-1) drugs are increasingly popular treatments for type 2 diabetes and obesity. However, they can cause unwanted side effects such as muscle loss (sarcopenia) and gastrointestinal issues. Tollo Health’s medical food products aim to alleviate these side effects, ensuring patients can continue their treatment regimens with minimal discomfort.
Supporting Patients with Long COVID
Long COVID, also known as Post-Acute COVID-19 Syndrome, refers to the ongoing health issues experienced by some individuals after recovering from the initial infection. Symptoms can include fatigue, shortness of breath, brain fog, and gastrointestinal problems. Tollo Health’s medical food products are designed to address these symptoms and provide general nutritional support.
Tollo’s Proprietary Medical Foods
Tollo Health’s first product, Galectovid™, is a medical food specifically formulated for the dietary management of Galectin-1 & 3 associated viral infections. Galectovid™ is designed to help support the immune system and reduce inflammation, potentially improving symptoms for patients with Long COVID and other viral conditions.
The Impact on Individuals
For individuals dealing with the side effects of GLP-1 drugs or the lingering symptoms of Long COVID, Tollo Health’s medical food products offer a potential solution. By addressing these specific health challenges, these products can help improve quality of life and enable individuals to better manage their conditions.
A Global Impact
With an estimated 50 million Americans living with diabetes and an even larger number struggling with obesity, the potential reach of GLP-1 drugs is vast. Furthermore, Long COVID is a growing concern, with an estimated 10% of COVID-19 survivors experiencing symptoms beyond the initial recovery period. Tollo Health’s medical food products could significantly impact the lives of millions, providing relief and support for those dealing with these conditions.
Conclusion
Wellgistics Health, Inc.’s collaboration with Tollo Health, LLC marks an important step forward in addressing the challenges posed by GLP-1 drug side effects and Long COVID. With Tollo’s innovative medical food products, individuals can look forward to improved quality of life and better management of their conditions. As the reach of these health issues continues to grow, the impact of this partnership could be felt on a global scale.
- Wellgistics Health, Inc. partners with Tollo Health, LLC to market medical food products for GLP-1 treatment side effects and Long COVID.
- Tollo Health’s offerings include solutions for muscle loss, gut discomfort, and persistent viral infections.
- Galectovid™, Tollo’s first product, is a medical food for the dietary management of Galectin-1 & 3 associated viral infections.
- These medical food products could significantly improve quality of life for millions dealing with diabetes, obesity, and Long COVID.
